On December 19, 2023 Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, reported that it will present two abstracts at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium in San Francisco, California, from January 18-20, 2024 (Press release, Triumvira Immunologics, DEC 19, 2023, View Source [SID1234638693]). The company will showcase clinical data from its ongoing Phase I/II studies investigating the safety and efficacy of autologous TAC-T cells targeting human epidermal growth factor receptor 2 (HER2) and Claudin 18.2 (CLDN 18.2), respectively, in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151, TACTIC-3 /NCT05862324).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The technology behind TAC01-HER2 and TAC01-CLDN18.2 stands as an innovative cell-based therapeutic modality, harnessing genetically engineered T cells derived autologously. These T cells are equipped with a T-cell Antigen Coupler (TAC) rationally designed to specifically recognize HER2 or CLDN18.2 within tumor cells.

"We are delighted to showcase the latest clinical developments of our Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting HER2+ relapsed or refractory solid tumors and our first in human phase 1/2 trial targeting CLDN18.2-positive solid tumors," said Dr. Paul Lammers, CEO of Triumvira Immunologics. "Our abstract presentations at the ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium underscores our dedication to pioneering advancements in autologous T cell therapy and unveils promising clinical data from our ongoing Phase I/II studies, shedding light on the safety and efficacy of autologous TAC01-HER2 and TAC01-CLDN18.2 in the challenging landscape of solid tumors."

Details of the abstracts for each poster presentation are as follows:

Abstract Number: 747
Title: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
Authors: Benjamin L. Schlechter, Ecaterina Dumbrava, Mridula George, Samuel Saibil, Marcus Butler, Antonio Giordano, Rishi Surana, Chih-Yi Liao, Jordan Weiss, Brooke Pieke, Miriam Gavriliuc, Emily Lichtenstein, Maria Apostolopoulou, Courtney Burke, Bushra Qureshi, Deyaa Adib, & Daniel Olson.
Session: Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Date: Thursday, January 18 at 11:45 a.m. – 1:15 p.m. Pacific Time
Location: Level 1, West Hall, Poster Board M2

Abstract Number: TPS419
Title: First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.
Authors: Ecaterina Dumbrava, Davendra Sohal, Daniel Olson, Samuel Saibil, Alejandro Urgelles, Maria Apostolopoulou, Amy Mueller, Kara Moss, Deyaa Adib, Benjamin Schlechter, & Syma Iqbal.
Session: Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Date: Thursday, January 18 at 11:45 a.m. – 1:15 p.m. Pacific Time
Location: Level 1, West Hall, Poster Board N4

On December 19, 2023 Illumina, Inc. (NASDAQ: ILMN) reported that its executives will be speaking at the following investor conference (Press release, Illumina, DEC 19, 2023, View Source [SID1234638692]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Presentation at 9:00am Pacific Time (12:00pm Eastern Time) immediately followed by a Q&A Session to begin at approximately 9:20am Pacific Time (12:20pm Eastern Time)

The webcast can be accessed through the Investor Info section of Illumina’s website at investor.illumina.com. A replay will be posted on Illumina’s website after the event and will be available for at least 30 days following.

On December 19, 2023 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024 (Press release, Harpoon Therapeutics, DEC 19, 2023, View Source [SID1234638691]). HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s own immune cells to kill tumor cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the ASCO (Free ASCO Whitepaper)-GU presentation are as follows:

Title: "Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting T-Cell Engager in Patients with Neuroendocrine Prostate Cancer (NEPC) and other Neuroendocrine Neoplasms (NEN)"

Abstract number: 121

Session: Rapid Oral Abstract Session A: Prostate Cancer

Session track: Prostate Cancer – Advanced | Prostate Cancer – Localized

Session date & time: Thursday, January 25, 2024 at 4:15 PM – 5:00 PM PST

Presenter: Himisha Beltran, M.D. | Dana-Farber Cancer Institute

Location: Level 3, Ballroom | Livestream

The presentation will also be available on Harpoon’s website under Publications following the session.

For more details about the ASCO (Free ASCO Whitepaper)-GU Annual Meeting, please visit: View Source

About HPN328
HPN328 targets delta-like canonical Notch ligand 3 (DLL3) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s own immune cells to kill tumor cells. HPN328 is being evaluated as monotherapy in an ongoing open-label, multicenter, two-part study to assess the safety, tolerability, and pharmacokinetics in patients with advanced cancers associated with the expression of DLL3.

In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to HPN328 for the treatment of SCLC.

On December 19, 2023 Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported that it will be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco to be held from January 8-11, 2024 (Press release, MediGene, DEC 19, 2023, View Source [SID1234638690]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan Healthcare Conference
View Source
Date: January 8-11, 2024
Location: The Westin St. Francis Hotel, San Francisco, CA

Members of Medigene’s management team will be available for one-on-one meetings to showcase the Company’s unique scientific platform, product pipeline, execution of its corporate strategy, and 2024 plans. Please contact Pamela Keck at [email protected] to schedule a meeting.

On December 19, 2023 XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported that it has entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital with certain funds managed by the credit platform of Blue Owl Capital Inc. (NYSE: OWL) (Press release, Xoma, DEC 19, 2023, View Source [SID1234638689]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Blue Owl financing provides us with significant non-dilutive capital to drive shareholder value through stock repurchases and additional royalty and milestone acquisitions," stated Brad Sitko, Chief Investment Officer of XOMA. "This capital infusion comes at an opportune time given the existing state of the biotech funding market, providing us with an opportunity to accelerate the growth of our royalty and milestones portfolio, which currently consists of two marketed products, two programs in or near registration, five assets in Phase 3 development, and over 60 assets in earlier stages of development."

"Blue Owl’s Life Science efforts are focused on credit, royalty, and equity investments in innovative healthcare and life sciences companies and products. We recognize the value embedded in XOMA’s differentiated royalty and milestone aggregation business strategy. Our long-established relationship with XOMA’s management team gives us confidence that they can continue building a balanced portfolio of current and future royalty-generating assets. This financing establishes a long-term partnership with XOMA, as we help broaden their access to capital for royalty and milestone monetization opportunities," said Sandip Agarwala, Managing Director at Blue Owl Capital.

Terms of the Agreement

XOMA has drawn down $130 million in principal from Blue Owl and has the option to draw another $10 million should the royalties received from VABYSMO (faricimab) sales on or prior to March 15, 2026, exceed a predetermined amount. XOMA is obligated to make semi-annual interest payments at a fixed rate of 9.875% per year until the royalty-backed loan is repaid, at which time VABYSMO royalty payments will revert back to XOMA. The loan is repayable over a 15-year period, although XOMA may repay it in full at any time during that period, subject to the terms of the loan. Additionally, XOMA has issued to Blue

Owl warrants to purchase an aggregate of up to 120,000 shares of XOMA’s common stock in three equal tranches with strike prices of $35.00, $42.50, and $50.00 per share, respectively, resulting in implied premiums of 122%, 170%, and 217% to the price of XOMA’s common stock at closing, respectively.

Advisors

Gibson, Dunn & Crutcher LLP served as XOMA’s legal advisor while Blue Owl was advised by Cooley LLP.